Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

Part of paid clinical trials in San Francisco, California.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00054132
Phase
PHASE2
Status
Completed

Conditions

  • Recurrent Breast Carcinoma
  • Stage IV Breast Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase II trial studies how well erlotinib hydrochloride and bevacizumab work in treating patients with stage IV breast cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving erlotinib hydrochloride and bevacizumab may be an effective treatment for breast cancer.

Key Dates

First listed
Feb 6, 2003
Start date
Dec 31, 2002
Status verified
Jun 2017
Primary completion
Apr 30, 2015
Completion
Apr 30, 2015

Study Design

Enrollment
38 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (erlotinib hydrochloride, bevacizumab)
    Patients receive erlotinib hydrochloride PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Level of EGFR Expression [ Time Frame: Up to 12 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
UCSF Medical Center-Mount ZionSan FranciscoCalifornia94115-
Memorial Sloan-Kettering Cancer CenterNew YorkNew York10065-

Find similar trials in San Francisco, CA

By research site
UCSF Medical Center-Mount Zion· San Francisco, CAMemorial Sloan-Kettering Cancer Center· New York, NY

Related Studies